Daratumumab in Primary Antiphospholipid Syndrome
for Autoimmune Disorders
Drug: Daratumumab
8 locations incl. Baltimore
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All·Age: 18 - 65
Code: NCT05671757·Phase 1, Phase 2·Recruiting